The embodiments of the present invention are directed to compounds that act as PDE4 inhibitors in the treatment of depression, anxiety and psychiatric disorders. The compounds have better activity and minimal emetogenic side effects. Such advantages are obtained as a result of the PDE4 inhibitor compound shown in the below structure (1): (I) wherein the substituents of the above structure (I) are defined in the specification, in free form or in the form of a pharmaceutically acceptable salts, solvates, ester, N-oxide thereof, processes for the preparation thereof, to pharmaceuticals containing such compounds, in particular for the use in diseases related to PDE4 inhibitions.
